Tigecycline

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Diarrhea

Conditions

Diarrhea, Clostridium Difficile

Trial Timeline

Jul 1, 2011 → Jul 1, 2013

NCT ID

NCT01401023

About Tigecycline

Tigecycline is a pre-clinical stage product being developed by Pfizer for Diarrhea. The current trial status is completed. This product is registered under clinical trial identifier NCT01401023. Target conditions include Diarrhea, Clostridium Difficile.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01560143	Approved	Completed	Mar 1, 2012	May 1, 2012	Obesity
NCT01401023	Pre-clinical	Completed	Jul 1, 2011	Jul 1, 2013	Diarrhea
NCT01072539	Pre-clinical	Completed	May 1, 2010	Apr 1, 2015	Complicated Skin and Skin Structure Infections
NCT00827541	Pre-clinical	Completed	Aug 1, 2008	Dec 1, 2010	Intra-Abdominal Infections
NCT00575094	Phase 3	Completed	Nov 1, 2007	Mar 1, 2008	Community-Acquired Infections
NCT00419991	Approved	Completed	Jan 1, 2007	May 1, 2008	Staphylococcal Infections
NCT00406237	Phase 1	Completed	Dec 1, 2006	Mar 1, 2009	Liver Cirrhosis, Biliary
NCT00488488	Pre-clinical	Completed	Nov 1, 2006	Mar 1, 2010	Infection
NCT00376324	Phase 1	Completed	Sep 1, 2006	Oct 1, 2008	Healthy Subjects
NCT00488306	Approved	Completed	Aug 1, 2006	Aug 1, 2007	Abdominal Abscess
NCT00488761	Approved	Completed	Jul 1, 2006	Aug 1, 2007	Skin Diseases, Infectious
NCT00136201	Phase 3	Completed	Nov 1, 2005	Dec 1, 2006	Abdominal Abscess
NCT00205816	Phase 3	Completed	Jan 1, 2004	Nov 1, 2005	Bacterial Infections
NCT00079989	Phase 3	Completed	Dec 1, 2003	Nov 1, 2005	Gram-Negative Bacterial Infections
NCT00079885	Phase 3	Completed	Nov 1, 2003	Jul 1, 2005	Community Acquired Pneumonia
NCT00079976	Phase 3	Completed	Oct 1, 2003	Jun 1, 2005	Gram-Positive Bacterial Infections
NCT00081744	Phase 3	Completed	Nov 1, 2002	Aug 1, 2004	Gram-Positive Bacterial Infections
NCT00600600	Phase 2	Completed	Apr 1, 2002	Dec 1, 2010	Mycobacterium Abscessus Lung Disease

Competing Products

20 competing products in Diarrhea

See all competitors

Product	Company	Stage	Hype Score
YM060 + Placebo	Astellas Pharma	Phase 3	77
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsules	Astellas Pharma	Phase 3	77
YM060	Astellas Pharma	Phase 3	77
Ramosetron	Astellas Pharma	Pre-clinical	23
Racecadotril Film-Coated Tablet (FCT) + Racecadotril Capsule	Johnson & Johnson	Phase 1	33
loperamide-simethicone + matching placebo	Johnson & Johnson	Approved	85
Racecadotril + Racecadotril + Racecadotril + Racecadotril	Johnson & Johnson	Phase 1	33
Loperamide/simeticone 2 mg/125 mg caplets + Loperamide/simeticone 2 mg/125 mg chewable tablets + Probiotic Saccharomyces boulardii 250 mg capsules	Johnson & Johnson	Approved	85
fidaxomicin + Placebo	Merck	Phase 3	77
Surotomycin + Placebo	Merck	Phase 1	33
Surotomycin + Placebo	Merck	Phase 1	33
OPT-80	Merck	Phase 2	52
fidaxomicin	Merck	Phase 2	52
RV5 (Pentavalent Rotavirus Vaccine)	Merck	Approved	85
LJN452 + Placebo to LJN452	Novartis	Phase 2	52
Octreotide Long Acting Release	Novartis	Phase 3	77
DNK333 + Placebo	Novartis	Phase 2	52
Probiotic Supplement	Roche	Pre-clinical	23
Etrasimod + Placebo + Corticosteroids	Pfizer	Phase 2	51
Calcium Carbonate + nelfinavir + lamivudine + loperamide + nelfinavir + lamivudine + zidovudine	Pfizer	Phase 3	76

Other Products from Pfizer